<DOC>
	<DOCNO>NCT02687178</DOCNO>
	<brief_summary>To evaluate efficacy blood pressure reduction , safety tolerability two different dosage canrenone add-on therapy patient already treat Angiotensin Converting-Enzyme Inhibitors ( ACE-I ) Angiotensin II Receptor Blockers ( ARBs ) diuretic maximum dosage .</brief_summary>
	<brief_title>Canrenone Add-on Patients With Essential Hypertension</brief_title>
	<detailed_description>To evaluate efficacy blood pressure reduction , safety tolerability two different dosage canrenone add-on therapy patient already treat Angiotensin Converting-Enzyme Inhibitors ( ACE-I ) Angiotensin II Receptor Blockers ( ARBs ) diuretic maximum dosage . In multi-centre , phase IV , randomize , control , open-label , parallel group trial , 180 Caucasian patient affect uncomplicated , essential hypertension , well control concomitant administration ACE-I ARBs diuretic maximum dosage enrol . At baseline patient randomize canrenone , 50 mg , canrenone 100 mg day , addition current therapy , three month . At baseline , 3 month evaluate : systolic ( SBP ) diastolic blood pressure ( DBP ) , pulse pressure ( PP ) , heart rate , fast plasma glucose ( FPG ) , homeostasis model assessment insulin ( HOMA-index ) , total cholesterol , HDL-cholesterol , triglyceride , LDL-cholesterol , sodium , potassium , calcium , magnesium , uric acid , estimate glomerular filtration rate ( eGFR ) , plasmatic urea , brain natriuretic peptide ( BNP ) , aldosterone , galectin-3 .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Canrenone</mesh_term>
	<criteria>Caucasian patient affect uncomplicated , essential hypertension , well control concomitant administration ACEI ARBs diuretic maximum dosage . diabetes mellitus secondary hypertension pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>